Phenelzine


Irreversible non-selective MAO inhibitor (hydrazine)

A first-generation hydrazine MAOI; a non-selective irreversible inhibitor still used for atypical and treatment-resistant depression.

Abstract

Phenelzine (2-phenylethylhydrazine; CAS 51-71-8; molecular formula C8H12N2; molecular weight 136.19) is a hydrazine class non-selective irreversible monoamine oxidase inhibitor approved by the FDA in 1961 under the trade name Nardil. The compound covalently inactivates both MAO-A and MAO-B by hydrazine-mediated cofactor adduction at the FAD prosthetic group; recovery requires de novo enzyme synthesis (approximately 14 to 21 days). The non-selective inhibition increases brain serotonin, norepinephrine, and dopamine concurrently, producing classical MAOI antidepressant pharmacology along with the well-known tyramine cheese-effect risk: dietary tyramine, normally degraded by intestinal MAO-A, accumulates and triggers hypertensive crisis through indirect sympathomimetic action. Plasma half-life is 11.6 hours, but the irreversible binding produces effective enzyme inhibition for 2 to 3 weeks. Hydrazine metabolism may produce hepatotoxic byproducts; chronic dosing requires hepatic monitoring. Approved for major depressive disorder; remains a benchmark for atypical depression with reverse vegetative features and for treatment-resistant cases where SSRIs and TCAs have failed.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph